A Study of HA121-28 Tablets in Advanced Biliary Tract Cancer

Status Terminated

Clinical Trial Summary

This study is a multicenter, open-label, single-arm phase II study to evaluate efficacy, safety, and pharmacokinetics characteristics of HA121-28 tablets in advanced biliary tract cancer (BTC). A total of approximately 30 subjects with advanced BTC will be enrolled. The subjects will undergo a 3 weeks-on and 1week-off treatment scheme with HA121-28 tablets 600 mg orally once daily in the 28-day cycle until disease progression or intolerable toxic reaction, whichever occurs first.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04784520
Study type	Interventional
Source	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Contact
Status	Terminated
Phase	Phase 2
Start date	June 22, 2021
Completion date	December 28, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05489211` - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)	Phase 2
Withdrawn	`NCT03110510` - FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study	Phase 2
Completed	`NCT05116891` - A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors	Phase 1/Phase 2
Completed	`NCT00380588` - Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer	Phase 2
Terminated	`NCT00090025` - XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors	Phase 3
Terminated	`NCT04066491` - Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC	Phase 2/Phase 3
Recruiting	`NCT05998447` - GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer	Phase 2
Recruiting	`NCT03718897` - Identification of Prognostic Gene Mutations in Biliary Tract Cancer Using Whole Genome Sequencing
Recruiting	`NCT05056116` - A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer	N/A
Recruiting	`NCT04692051` - A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer	Phase 2
Terminated	`NCT04057365` - Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)	Phase 2
Recruiting	`NCT04907643` - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes	N/A
Completed	`NCT02829918` - Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers	Phase 2
Recruiting	`NCT04584996` - CIRcular and Non-coding RNAs as Clinically USeful Biomarkers in Pancreaticobiliary Cancers
Completed	`NCT02579616` - Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy	Phase 2
Recruiting	`NCT05052099` - Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer	Phase 1/Phase 2
Recruiting	`NCT01494363` - Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer	Phase 2
Completed	`NCT00753675` - Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer	Phase 2
Terminated	`NCT00630890` - Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)	Phase 1
Recruiting	`NCT04445532` - Hepatobiliary Tumors Tissue Samples Acquisition